Acadia Pharmaceuticals has recently achieved a crucial legal victory, securing extended patent protection for its Parkinson's disease drug, Nuplazid (pimavanserin). The U.S. District Court for the District of Delaware ruled in favor of Acadia's '721 formulation patent, extending protection for the 10 mg tablet until 2037 and the 34 mg capsule until 2038. Additionally, the '740 composition of matter patent was upheld, safeguarding Nuplazid until 2030, according to Acadia's official release.
These court rulings have had a significant positive impact on Acadia's stock performance. As reported by Pharmaceutical Technology, the company's stock price surged by 24.5% following the favorable court decision. This comes after Acadia filed lawsuits in 2020 against multiple pharmaceutical companies to protect Nuplazid from unauthorized generic versions entering the market.
Approved by the FDA in 2016, Nuplazid is used to treat hallucinations and delusions associated with Parkinson's disease psychosis. These recent legal victories help reinforce Acadia's competitive position in the market by ensuring prolonged exclusivity for Nuplazid, backed by solid patent protections.